Dawei Shi

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4378975/publications.pdf

Version: 2024-02-01

		1683354	1719596
8	56	5	7
papers	citations	h-index	g-index
8	8	8	93
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	Linezolid and the risk of lactic acidosis: Data mining and analysis of the FDA Adverse Event Reporting System. Journal of Clinical Pharmacy and Therapeutics, 2020, 45, 1422-1426.	0.7	11
2	Proton Pump Inhibitor Therapy and Hepatic Encephalopathy Risk in Cirrhotic Patients: A Systematic Review with Meta-analysis. Clinical Drug Investigation, 2019, 39, 847-856.	1.1	8
3	Hepatotoxicity-Related Adverse Effects of Proton Pump Inhibitors: A Cross-Sectional Study of Signal Mining and Analysis of the FDA Adverse Event Report System Database. Frontiers in Medicine, 2021, 8, 648164.	1.2	8
4	An investigation into possible interactions among four vascular epidermal growth factor receptor-tyrosine kinase inhibitors with gefitinib. Cancer Chemotherapy and Pharmacology, 2021, 87, 43-52.	1,1	7
5	Clinical characteristics and risk factors of severe hyponatremia in cirrhotic patients treated with terlipressin. Journal of Clinical Pharmacy and Therapeutics, 2020, 45, 191-198.	0.7	6
6	Characterization of binding interaction between magnesium isoglycyrrhizinate and human serum albumin. Spectrochimica Acta - Part A: Molecular and Biomolecular Spectroscopy, 2020, 234, 118245.	2.0	6
7	Hypoglycemia Induced by Hydroxychloroquine Sulfate in a Patient Treated for Connective Tissue Disease Without Diabetes Mellitus. Clinical Therapeutics, 2020, 42, 940-945.	1.1	6
8	Anaplastic lymphoma kinase tyrosine kinase inhibitorâ€induced hepatic failure in lung cancer patients: A study of signal mining and analysis of the FDA adverse event reporting system database. Journal of Clinical Pharmacy and Therapeutics, 2021, 46, 1148-1154.	0.7	4